Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $12.74 USD
Change Today +0.16 / 1.27%
Volume 1.4M
ELGX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 5:20 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

endologix inc (ELGX) Snapshot

Open
$12.11
Previous Close
$12.58
Day High
$12.83
Day Low
$12.11
52 Week High
04/6/15 - $18.07
52 Week Low
09/29/14 - $10.29
Market Cap
863.5M
Average Volume 10 Days
724.1K
EPS TTM
$-0.79
Shares Outstanding
67.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENDOLOGIX INC (ELGX)

Related News

No related news articles were found.

endologix inc (ELGX) Related Businessweek News

No Related Businessweek News Found

endologix inc (ELGX) Details

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular repair (EVAR) products, including EVAR stent graft and catheter delivery system under the brand names Powerlink, IntuiTrak, AFX, and VELA Proximal Endograft. It also provides endovascular sealing (EVAS) product that is based on the Nellix platform to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which attach to the main body of its EVAR device, allowing physicians to customize it to fit the patient’s anatomy; and accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths. It sells its products through direct sales force, network of agents, and independent distributors. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

590 Employees
Last Reported Date: 03/2/15
Founded in 1992

endologix inc (ELGX) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $930.9K
President
Total Annual Compensation: $580.2K
Chief Financial Officer and Secretary
Total Annual Compensation: $425.5K
Vice President of Human Resources
Total Annual Compensation: $169.5K
Vice President of Quality
Total Annual Compensation: $346.1K
Compensation as of Fiscal Year 2014.

endologix inc (ELGX) Key Developments

Endologix Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year 2015

Endologix Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue was $39,479,000 compared to $38,327,000 a year ago. Loss from operations was $12,150,000 compared to $3,772,000 a year ago. Net loss before income tax benefit was $12,940,000 compared to $9,073,000 a year ago. Net loss was $13,001,000 or $0.19 basic and diluted per share compared to $8,993,000 or $0.14 basic and diluted per share a year ago. Adjusted net loss was $11,998,000 or $0.18 per share compared to $3,618,000 or $0.06 per share a year ago. Adjusted EBITDA was $8,085,000 or $0.12 per share compared to $947,000 or $0.02 per share a year ago. For the quarter, the company reported total revenue of $76,149,000 compared to $71,591,000 a year ago. Loss from operations was $21,813,000 compared to $9,088,000 a year ago. Net loss before income tax benefit was $24,062,000 compared to $3,562,000 a year ago. Net loss was $24,215,000 or $0.36 basic and diluted per share compared to $3,698,000 or $0.06 basic and diluted per share a year ago. Adjusted net loss was $21,289,000 or $0.32 per share compared to $9,099,000 or $0.14 per share a year ago. Adjusted EBITDA was $13,584,000 or $0.20 per share compared to $3,997,000 or $0.06 per share a year ago. The company revised earnings guidance for the year 2015. For the year, the company is revising its revenue guidance (based on an estimated foreign currency exchange rate) to be in the range of $154 million to $157 million, or growth of 4% to 6%, down from previous reported revenue guidance of $159 million to $165 million, or growth of 8% to 12% over 2014. This updated revenue guidance equates to constant currency guidance in the range of $160 million to $163 million, or constant currency growth of 8% to 10% from 2014. The company is also updating its GAAP loss per share guidance to a range of $0.72 to $0.77 and an adjusted loss per share guidance to a range of $0.59 to $0.64, down $0.08 per share on a GAAP and adjusted basis from prior guidance due to the lower revenue guidance and increased reserve for product inventory during the second quarter. The company expects gross margin to be about 68% for the full year 2015, down from previous guidance of 70%.

Endologix Inc. to Report Q2, 2015 Results on Aug 03, 2015

Endologix Inc. announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on Aug 03, 2015

Endologix Inc., Q2 2015 Earnings Call, Aug 03, 2015

Endologix Inc., Q2 2015 Earnings Call, Aug 03, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ELGX:US $12.74 USD +0.16

ELGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $24.07 USD -0.68
Cardiovascular Systems Inc $22.98 USD -0.51
CryoLife Inc $9.80 USD -0.06
Spectranetics Corp/The $16.39 USD -0.04
Vascular Solutions Inc $33.69 USD -0.46
View Industry Companies
 

Industry Analysis

ELGX

Industry Average

Valuation ELGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.6x
Price/Book 8.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDOLOGIX INC, please visit www.endologix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.